MajorDirect thrombin inhibitor×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
Dabigatran etexilate is a substrate of P-glycoprotein (P-gp), an efflux transporter (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Protease inhibitors such as ritonavir and its combinations with other protease inhibitors affect P-gp either as inhibitors or as inducers. They have not been studied with dabigatran (dabigatran SmPC, EMA). According to the ritonavir SmPC, serum levels of dabigatran may rise because ritonavir inhibits P-gp (ritonavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With multiple doses of nirmatrelvir/ritonavir, the dabigatran area under the concentration–time curve (AUC) rose by 94% and peak concentration by 133% (nirmatrelvir/ritonavir SmPC, EMA).
Symptoms
Dabigatran can cause occult or overt bleeding in any tissue or organ, and severe bleeding can lead to disability or death (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). Common adverse reactions include nosebleeds, gastrointestinal bleeding, bleeding into the skin and genitourinary bleeding, including blood in the urine. In atrial fibrillation, anaemia is also common (dabigatran SmPC, EMA). Bleeding complications can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (dabigatran SmPC, EMA). The risk of bleeding is higher in people aged 75 years or older, in moderate renal impairment (creatinine clearance 30–50 mL/min) and with other drugs that affect haemostasis (dabigatran SmPC, EMA).
Management
The combination is not contraindicated, but dabigatran is not recommended with protease inhibitors such as ritonavir and its combinations with other protease inhibitors (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). With nirmatrelvir/ritonavir for COVID-19, reduce the dabigatran dose or avoid the combination (nirmatrelvir/ritonavir SmPC, EMA). The ritonavir SmPC says to consider clinical monitoring, a lower dabigatran dose or both when the two drugs are given together (ritonavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the European Heart Rhythm Association practical guide, dabigatran with HIV protease inhibitors such as ritonavir is marked red (EHRA 2021). Red means contraindicated or not advisable because of raised plasma levels. Dabigatran levels may change in either direction, and there are no clinical or pharmacokinetic data on this pair (EHRA 2021). The US dabigatran label says to avoid P-gp inhibitors in patients with creatinine clearance below 50 mL/min. This applies to treatment of deep vein thrombosis and pulmonary embolism and to prophylaxis after hip replacement (dabigatran label, US Food and Drug Administration, FDA). If the drugs are nevertheless combined, watch closely for signs of bleeding and anaemia. If haemoglobin, haematocrit or blood pressure falls without explanation, look for a bleeding site. Stop dabigatran if severe bleeding occurs. In adults with life-threatening or uncontrolled bleeding, consider the specific reversal agent idarucizumab (dabigatran SmPC, EMA). Assess renal function as creatinine clearance before starting and whenever a decline is suspected. Dabigatran is contraindicated when creatinine clearance is below 30 mL/min (dabigatran SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ritonavir (nº registro 81039), sección 4.5 (2025)– AEMPS, CIMA, nº registro 81039, sección 4.5
- FDA: Pradaxa (dabigatran etexilate) capsules prescribing information (2025)– FDA label, DailyMed setid ba74e3cd-b06f-4145-b284-5fd6b84ff3c9, sections 2.2, 5.5, 7.1–7.3, figure 3.1
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Nirmatrelvir/ritonavir (EU/1/22/1625), sección 4.5 (2026)– EMA, Paxlovid 150 mg + 100 mg comprimidos recubiertos con película (Pfizer Europe MA EEIG, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1221625001, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4 y 4.5
- EMA: Ficha técnica: Dabigatrán etexilato, Pradaxa 150 mg (EU/1/08/442), sección 4.5 (2026)– EMA, Pradaxa 150 mg cápsulas duras (Boehringer Ingelheim International, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08442011, consultada 30.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 (tabla 4), 4.5 (tabla 8) y 4.8